Articles On Kazia Therapeutics (ASX:KZA)
Title | Source | Codes | Date |
---|---|---|---|
Dr Boreham’s Crucible: Does this biotech have the horsepower to become ‘the next Neuren’?
What’s in a name? Not much, according to the CEO of the now cashed-up Percheron, Dr James Garner. Formerly known as Antisense Therapeutics, the rare disease specialist changed its name to Percheron in January. Percheron means ‘draught horse... |
Stockhead | KZA | 2 months ago |
Health Check: Farewell, adieu as Argent Biopharma holders back ASX delisting
Argent Biopharma packs its bags for London on a one-way ticket Patrys shares slump 50% on cancellation of key drug program Painchek targets US market for its pain detection app Health Check is renowned biotech journo Tim Boreham’s daily... |
Stockhead | KZA | 2 months ago |
Check Up: Biden-Xi meeting could finally end opioids crisis in the US; and recent ASX biotech winners
Xi and Biden set to agree on restricting fentanyl Fentanyl is a synthetic opioid responsible for the opioids epidemic in the US We look at the best performing health stocks over the past couple of weeks China’s President Xi is expected... |
Stockhead | KZA | 1 year ago |
Closing Bell: Friday takes a bite out of ASX, even as biotech and lithium small caps run amok
The ASX has ended the week lower, down 0.55pc on Friday Healthcare Sector remains defiant Small caps led by medtech names and Lake Johnston lithium hunters The fickle Aussie sharemarket has given back on Friday all that it has made thi... |
Stockhead | KZA | 1 year ago |
Closing Bell: ASX gains trimmed by deflating Chinese data, however it’s Kristmas at Krakatoa with thick peggies for all
The ASX has closed higher Healthcare leads sector gains Small caps led by KTA and FG1 The Aussie sharemarket has trimmed the fat off this morning’s substantial gains – at one stage there we were easing past the 7,350 mark and off to th... |
Stockhead | KZA | 1 year ago |
Closing Bell: Smart and casual, ASX makes it five in a row; next up – rates and horse races
ASX200 closes +0.28% higher Healthcare leads gains, ASX All Gold rises over +3% Small caps led by takeover target Whispir The Australian sharemarket has ended higher on the first day of what is certain to be another week of intensely tr... |
Stockhead | KZA | 1 year ago |
10 at 11ish: Who got a takeover bid and who is backing out of one?
Good morning, and welcome to Stockhead’s Top 10 at shortly-before-11-ish, to highlight the best (and sometimes worst) performing ASX stocks in morning trade using live data, to provide a short, sharp update to help frame the trading day by... |
Stockhead | KZA | 1 year ago |
ASX October winners: The 50 best ASX stocks as Israel-Hamas escalation adds further pressure to fragile markets
The S&P ASX 200 fell -3.8% in October with mid-caps falling -6.94% and small-caps down -5.45% for the month S&P ASX 200 Energy was the only sector that closed October in the black with all Australian equity factors in red Dimerix... |
Stockhead | KZA | 1 year ago |
Check Up: Why Goldman Sachs won’t change its ratings on 3 ASX stocks despite Ozempic-driven selloff
News relating to Novo Nordisk’s Ozempic has led to a selloff in some ASX stocks CSL, FPH, and RMD fell heavily last week But Goldman analysts say they won’t change ratings on these 3 stocks Goldman Sachs analysts said they will make no... |
Stockhead | KZA | 1 year ago |
Hot Money Monday: What is momentum trading, and which ASX explorers are riding high on it?
Momentum trading involves taking advantage of, and making profits from, upward trends in a stock. There’s a bit of risk involved in momentum trading because in essence, you’re making a decision to buy a stock based on recent buying activiti... |
Stockhead | KZA | 1 year ago |
Traders’ Diary: A week of War, Worry and Wall Street earnings
The Week That Was The world looks very different this week after the addition of what Barclays economic team calls ‘a complex cocktail of geopolitical risk, mixed macro data, a nervous oil market,’ and a US Fed finding nice things to say ab... |
Stockhead | KZA | 1 year ago |
ASX Today: Stocks to watch on Friday & US inflation
ASX futures were down 0.82 per cent heading into 8.30 am AEDT. The market is set for a day in the red after US inflation came in hotter than expected overnight at 3.7 per cent, rising 0.3 per cent. That was the core read, which excludes... |
themarketherald.com.au | KZA | 1 year ago |
Closing Bell: Local markets ignore the conflict, follow the money to a fifth day of wins
ASX 200 closes higher for a fifth straight day All 11 Sectors make it home for supper Small caps led by Zuleika and Creasy It’s fair to say the little battler of an Aussie sharemarket’s put in a real decent day’s work. As various part... |
Stockhead | KZA | 1 year ago |
ASX Health Stocks: Kazia says goodbye to the ASX; IMEHXS wins $2m contract in Colombia
Kazia to de-list from ASX and maintain its NASDAQ listing IMEXHS wins $2m contract with Colombia’s National Police Force Pacific Edge says its test volumes fell in Q2 Kazia to de-list from ASX Oncology-focused drug development company K... |
Stockhead | KZA | 1 year ago |
Top 10 at 11: Lithium and gold are popular again, but Kazia’s de-listing and falling fast
Stockhead’s Top 10 at shortly-before-11-ish, produced as on-time as humanly possible, despite being handicapped by some decidedly non-human and highly-unfriendly technology. On a slightly-related note, if anyone out there needs parts for an... |
Stockhead | KZA | 1 year ago |
Closing Bell: Local markets end 0.4pc higher led by big banks and a few small biotechs
Benchmark index finishes Friday ahead +0.4% Sectors led by Financials Small caps dominated by Dimerix The ASX200 is up +0.4% at the end of Friday trade, making the week a 1% loss, which we’ll take at this stage. US equities ticked l... |
Stockhead | KZA | 1 year ago |
ASX Health Stocks: Proteomics soars 13pc after US sets reimbursement price for PromarkerD
PIQ came out of trading suspension and surged 13pc PIQ says the US has set a national reimbursement price for PromarkerD Kazia awarded a late breaking oral presentation for paxalisib Proteomics International Laboratories (ASX:PIQ) surge... |
Stockhead | KZA | 1 year ago |
ASX Today: Stocks to watch on Friday
Futures indicate the ASX will open positively this morning, buoyed by tech gains in the US and the encouraging news of a drop in oil prices. Here are some ASX-listed companies with news out today: Kazia Therapeutics (KZA) will present... |
themarketherald.com.au | KZA | 1 year ago |
Check Up: How supramolecular technology is used in biotech, and why L’Oréal wants to get its hands on it
L’Oréal to take minority stake in Chinese startup Shinehigh Innovation Shinehigh is developing supramolecular technology which could be used in the fashion industry Best and worst performing ASX biotechs over the past couple of weeks Be... |
Stockhead | KZA | 1 year ago |
ASX cancer stocks guide: Here’s everything you need to know
According to the World Health Organisation (WHO), cancer is the leading cause of death globally. WHO defines cancer as a generic term for a large group of diseases that can affect any part of the body with malignant tumours and neoplasms. W... |
Stockhead | KZA | 1 year ago |
Check Up: What is the FDA emergency use authorisation, and which ASX stocks were given approval?
The FDA has just approved an emergency use authorisation for new Covid-19 vaccines What is emergency use authorisation, and which ASX stocks have got it? We look at the best and worst performing ASX biotechs over the couple of weeks On... |
Stockhead | KZA | 1 year ago |
ASX Biotech August Winners: Sector down despite CSL and Cochlear’s strong results, but don’t panic…
Earnings reports dominated headlines in August Despite solid results from ASX healthcare giants, the sector finished lower We take a look at which ASX healthcare stocks performed the best in August August was all about earnings, and des... |
Stockhead | KZA | 1 year ago |
Check Up: Australian biotech sector continues to be a magnet for US investors
Australian biotech has attracted US investments in the last five years Among ASX stocks to get funded from the US include Opthea We look at the best and worst performing ASX biotechs over the past month The Australian biotech sector co... |
Stockhead | KZA | 1 year ago |
Check Up: Biotech is worth ‘US$4 trillion in 10 years’, and here’s where the smart money will go
Biotech could be a US$4 trillion industry in 10 years Genetic engineering and weight loss are two growing themes in the space We look at the best and worst performing ASX biotechs over the past month Steve Jobs used to say that the most... |
Stockhead | KZA | 1 year ago |
ASX Biotech Winners in July: Down but far from out, here’s why biotechs could stage a comeback
The end of pandemic and higher rates have subdued biotech market But there are signs now the sector is making a comeback We take a look at the ASX Biotech Winners in July The Covid-19 pandemic had produced windfalls for and attracted fa... |
Stockhead | KZA | 1 year ago |
Closing Bell: RBA pauses, lithium leaps and ASX 200 finishes 0.54pc to the good
The ASX 200 had a positive finish to the day on the whole, on the back of the rates pause from the RBA Sectors were a green scene, with IT and Staples leading the way Standout small caps: Viridis, Imricor and Baby Bunting, among several ot... |
Stockhead | KZA | 1 year ago |
Top 10 at 10: Anyone know why Mobilicom just rocketed 425pc?
Stockhead’s Top 10 at 10, published at ~10.30am each trading day, highlights the best (and worst) performing ASX stocks in morning trade using live data. It’s a short, sharp update to help frame the trading day by showing the biggest movers... |
Stockhead | KZA | 1 year ago |
FDA fast-track designation for Kazia Therapeutics' cancer candidate
Kazia Therapeutics (ASX:KZA) has announced that its lead program, paxalisib, has been awarded Fast Track Designation by the US FDA. |
BiotechDispatch | KZA | 1 year ago |
ScoPo’s (actually Wilkie’s) Powerplays: ASX health stocks up as Avita Medical gets US FDA green light
Avita Medical receives US FDA premarket approval for its RECELL System to treat vitiligo Telix will buy UK medical device firm Lightpoint Medical and its radio-guided surgery business SENSEI Antisense in strong position with new CEO, forme... |
Stockhead | KZA | 1 year ago |
ASX Biotech Winners in May: We’re finally seeing signs of life on the back of another clinical breakthrough
Biotech is making a comeback in 2023 There’s been a couple of breakthroughs on the ASX this year We take a look at the ASX biotech winners in May There are clear signs the biotech sector is springing back to life after a disappointing 2... |
Stockhead | KZA | 1 year ago |
Kazia Therapeutics participates in 'Cancer Moonshot Brain Cancers' forum
Kazia Therapeutics (ASX:KZA) recently attended and participated in the Cancer Moonshot Brain Cancers Forum on Glioblastoma and Diffuse Intrinsic Pontine Glioma at the White House in Washington DC. |
BiotechDispatch | KZA | 1 year ago |
Orphan drug designation has a direct impact on drug pricing for these pharma players
Orphan diseases are those impacting less than 200,000 patients Orphan drug designation ensures an exclusivity period for pharma companies The average orphan drug in the US retails for US$7,000 per month Rare or ‘Orphan’ diseases affect... |
Stockhead | KZA | 1 year ago |
ASX Health Stocks: Little Green Pharma gets French deal extension; FDA approves Immuron trial
Little Green Pharma gets extended contract from the French government US FDA’s decision paves the way for a clinical involving Immuron’s drug Antisense Therapeutics announces new CEO Cannabis stock Little Green Pharma (ASX:LGP) has been... |
Stockhead | KZA | 1 year ago |
TMH Spotlight: Halo Food Co (ASX:HLF) shares soar on multi-million dollar deal, Arcadia Minerals (ASX:AM7) hits copper and gold at Karibib
The ASX 200 opened half a per cent higher this morning, with 9 of 11 sectors positive in intraday trade. Among them was the consumer staples sector, which was up nearly one per cent. Small-cap dairy product producer Halo Food Co (HLF)... |
themarketherald.com.au | KZA | 1 year ago |
Kazia Therapeutics (ASX:KZA) promotes Chief Medical Officer John Friend to CEO
Kazia Therapeutics (KZA) promotes its Chief Medical Officer, John Friend, to the role of CEO following the sudden resignation of James Garner, who held the position up until now Dr Friend’s appointment is effective immediately, with plan... |
themarketherald.com.au | KZA | 1 year ago |
ASX Today: Stocks to watch on Monday
The ASX is expected to open higher on a new week after gains continued across New York on Friday night in the aftermath of quarterly reporting season. Elsewhere, eyes are fixated on central banks across the world this week, with the RBA... |
themarketherald.com.au | KZA | 1 year ago |
Check Up: Healthcare is ripe for AI disruption, and Telix Pharma’s first $100m quarterly sales
Artificial intelligence is set to disrupt the healthcare sector AI could also help in drugs discovery Telix delivers first quarterly revenue of $100 million Moody’s Analytics’ chief economist, Mark Zandi, said the healthcare industry’s... |
Stockhead | KZA | 1 year ago |
Top 10 at 10: The gold, copper and HR stocks leading the winners in early trade Friday
Stockhead’s Top 10 at 10, published at ~10.30am each trading day, highlights the best (and worst) performing ASX stocks in morning trade using live data. It’s a short, sharp update to help frame the trading day by showing the biggest movers... |
Stockhead | KZA | 1 year ago |
CLOSING BELL: Aussies find a cost of living crisis fix, by stealing everything not nailed down
The ASX slid to close flat today, after realising we were in danger of making some money Materials and Energy enjoyed a boost from Chinese manufacturing data Retail theft rates have soared as the cost of living crisis hits hard around the... |
Stockhead | KZA | 1 year ago |
Check Up: The FDA refuses to give CBD a green light, but market doesn’t seem to care
The FDA declined regulate CBD-based supplements and food, citing safety reasons CBD products have grown exponentially in the marketplace We take a look at what it all means for the cannabis industry The US FDA announced last week that:... |
Stockhead | KZA | 1 year ago |
ASX January Winners: The S&P 200 just had its best start to any year. Who’s led the way for small caps?
The S&P ASX 200 rose 7.64%, in its best start to a year ever as global markets rally In a strong start to 2023 the S&P/ASX Emerging Companies index (XEC) rose ~8% in January Graphite explorer Lincoln Minerals soars more than 500% s... |
Stockhead | KZA | 1 year ago |
Aus shares close 0.07% lower but rise 6.2% in January
ShareCafeAus shares close 0.07% lower but rise 6.2% in January by Peter Milios Australian shares fluctuated on Tuesday with a 0.4 per cent gain and later 0.2 per cent loss. Consumer stocks led the gains, up 2.3 per cent, while tech stocks... |
ShareCafe | KZA | 1 year ago |
High cost of living causes a fall in retail sales: ASX up 0.22% at noon
ShareCafeHigh cost of living causes a fall in retail sales: ASX up 0.22% at noon by Peter Milios Retail sales in Australia fell 3.9% in December, surprising expectations for a 0.2% decline. The ABS Head of Retail Statistics noted that the... |
ShareCafe | KZA | 1 year ago |
Check Up: Japan’s startup OUI wants to halve the world’s blindness with its smartphone device
Japanese startup OUI is on a mission to halve the world’s blindness with its smartphone-based device Which ASX healthcare companies also have smartphone-based products? A quick look at the best and worst ASX healthcare stocks over the past... |
Stockhead | KZA | 1 year ago |
CLOSING BELL: Because sometimes you just know when enough is enough
ASX 200 holds steady around +0.8% since lunch Australian Pacific Coal CEO David Conry has left the company. Abruptly. Bain Capital making all the right noises about bringing Virgin back to the bourse All up, it’s been a pretty tidy old... |
Stockhead | KZA | 1 year ago |
Kazia Therapeutics (ASX:KZA) raises $4.5m and launches SPP
Kazia Therapeutics (KZA) launches $4.5 million via a placement to drive its clinical program toward several critical inflection points The placement comprises an unconditional and a conditional placement of at 11 cents a share, a 13 per... |
themarketherald.com.au | KZA | 1 year ago |
Top 10 at 10: Today is all about critical mineral discoveries, high grade gold, and large lithium loans
Stockhead’s Top 10 at 10, published at ~10.30am each trading day, highlights the best (and worst) performing ASX stocks in morning trade using live data. It’s a short, sharp update to help frame the trading day by showing the biggest movers... |
Stockhead | KZA | 1 year ago |
CLOSING BELL: The ASX engine rooms roar to life, delivering a 1.2% touch worthy of Midas himself
What a solid day it’s been for the ASX today, with the benchmark maintaining a strong run past +1.1% for the afternoon, to finish at +1.18% when the bell finally rang, and the old ladies running the ASX called “pencils down” and everyone go... |
Stockhead | KZA | 1 year ago |
CLOSING BELL: It’s the sound the market makes at the end of the day… dingaling
The benchmark looks like it’s been working hard, but really not much has changed Turaco Gold hits solid results, goes up $0.01 (which is actually 17.2%, so that’s a good thing) I don’t know why there has to be 3 bullet points. When I was a... |
Stockhead | KZA | 1 year ago |
ASX November Winners: Who’s leading the way for small caps as global markets rally?
Global share markets rally continue to rally in November despite ongoing economic and geopolitical pressures Avenira led the gainers in November after reporting a positive update on its proposed DSO Phosphate Project Gut health company Mic... |
Stockhead | KZA | 2 years ago |